BSC statement regarding the use of TNK for treatment of acute ischemic stroke

by | 18 Sep 2024 | News, professionals, Research

The Belgian Stroke Council is currently awaiting a decision by FAGG and RIZIV/INAMI regarding marketing and reimbursement of tenecteplase (TNK) for treatment of acute ischemic stroke in Belgium.

Based on the current evidence obtained from randomized, controlled trials comparing TNK with alteplase (tPA), the European Stroke Organisation (ESO) has stated that TNK (dosed at 0.25mg/kg) may be used as an alternative for tPA in eligible patients with acute ischemic stroke. The effectiveness and safety of TNK is comparable to tPA. Acute stroke patients with an occlusion of a large intracranial blood vessel may particularly benefit from TNK.

For more information, we refer to the BSC opinion statement and the ESO guideline on the use of TNK, attached to this post.

BSC opinion statement in dutch

BSC opinion statement in french

ESO guideline on TNK use

Remboursement Xarelto 2,5 mg

by | 13 Feb 2024 | News, professionals

We are delighted to announce that neurologists also have been recognised for the reimbursement of Xarelto 2.5mg in coronary artery disease (CAD) and peripheral artery disease PAD), since February 1, 2024.
Furthermore, the duration of acceptance has been changed, since the 3-year limit has been withdrawn.

 

Please find attached Bayer’s information letter: BE.XAR.VAE_Remboursement CADPAD_FR

Actilyse vials with latex plugs that could also contain traces of Gentamycine.

by | 29 Nov 2023 | News, professionals

Dear members of the SB,

As part of the strategy to resolve the worldwide shortage of thrombolytic therapy, the BSC has been informed that Boehringer-Ingelheim will temporarily produce Actilyse vials with latex plugs that could also contain traces of Gentamycine. These vials could be encountered in your local hospital from the end of October onward (and will likely be produced for several months).

BI states that boxes containing vials with latex plugs and vials that could contain traces of Gentamycine will be clearly labeled by stickers (see photograph). These vials should never be administered to patients with a latex/rubber sensitivity or sensitivity to Gentamycine.

Joint Statement ESO and SAFE commemorate European Stroke Awareness Day 9 May 2023

by | 9 May 2023 | campagne, Event, News, patients, professionals, resources

Europe is failing to provide adequate stroke care and support
The scale of stroke care crisis is laid bare by new data release

New data collected as part of the Stroke Action Plan for Europe (SAP-E) Stroke Service Tracker reveals the
gross inequity of access to care and support for stroke patients and stroke survivors across Europe.

The SAP-E was launched in 2018 to provide a framework for European governments to improve stroke care
and support for all European citizens. As part of this plan, data from 36 countries across Europe, covering
12 key areas of improvement, has been collected in and is available via the SAP-E website.

SAP-E Joint Statement for ESAD 2023